04:23:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-28 Årsstämma 2024
2024-05-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1


ListaFirst North Stockholm
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2023-08-17 09:05:00

Ziccum AB is to present at the BioFuture 2023 conference in New York City, October 4 – 6 2023, a key industry event attracting top-tier investors to evaluate innovators in biopharmaceuticals.

Ziccum CEO Ann Gidner will present Ziccum’s unique drying technology for biopharmaceuticals, LaminarPace, and its market potential at BioFuture 2023. Uniquely, LaminarPace enables new delivery and greatly improved stability for biopharmaceuticals, potentially making new treatments available for patients world-wide. Most importantly, the enormous potential of the mRNA/LNP therapy and vaccine platform could be unlocked if delivery and stability challenges were solved. Ziccum presented excellent data in mRNA/LNP trials during spring 2023, followed by two prestigious industrial feasibility agreements being signed.

Driven by public & private initiatives, BioFuture has emerged as a hub for innovation in the life sciences and digital health space. LifeSciNY is allocating 500 MUSD in investment to build the Life Science arena.

Ziccum has been represented at a series of high-profile industry events throughout the year – including the Global mRNA Therapeutic Summit in Boston, Mass. and the invitation-only Longwood Healthcare Leaders Spring Conference. In June / July, Ziccum reported signing two major new Evaluation Agreements for Feasibility Studies for mRNA/LNP projects with major Pharmaceutical/Biotech corporations leading the mRNA-field.

Ann Gidner: “it is exciting to participate at BioFuture in New York. We are proud to be presenting the Ziccum core concept, successful data and the very significant mRNA market outlook to US investors, taking a next step in our international outreach”.